Twist Bioscience Co. (NASDAQ:TWST) SVP Sells $45,322.00 in Stock

Twist Bioscience Co. (NASDAQ:TWST) SVP Paula Green sold 860 shares of Twist Bioscience stock in a transaction that occurred on Friday, December 6th. The shares were sold at an average price of $52.70, for a total transaction of $45,322.00. Following the completion of the sale, the senior vice president now owns 133,715 shares in the company, valued at $7,046,780.50. This trade represents a 0.64 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Paula Green also recently made the following trade(s):

• On Monday, November 11th, Paula Green sold 1,347 shares of Twist Bioscience stock. The shares were sold at an average price of $48.00, for a total transaction of $64,656.00.
• On Wednesday, November 6th, Paula Green sold 5,519 shares of Twist Bioscience stock. The stock was sold at an average price of $44.60, for a total transaction of $246,147.40.
• On Monday, November 4th, Paula Green sold 1,057 shares of Twist Bioscience stock. The shares were sold at an average price of $41.56, for a total value of $43,928.92.
• On Wednesday, October 2nd, Paula Green sold 3,310 shares of Twist Bioscience stock. The stock was sold at an average price of $43.21, for a total value of $143,025.10.
• On Friday, September 20th, Paula Green sold 297 shares of Twist Bioscience stock. The shares were sold at an average price of $46.94, for a total value of $13,941.18.

Twist Bioscience Stock Down 3.0 %

Shares of TWST stock opened at $47.39 on Friday. Twist Bioscience Co. has a 52 week low of $27.41 and a 52 week high of $60.90. The company has a 50-day simple moving average of $44.85 and a 200 day simple moving average of $46.60.

Institutional Investors Weigh In On Twist Bioscience

Institutional investors have recently made changes to their positions in the company. Wilmington Savings Fund Society FSB bought a new position in shares of Twist Bioscience during the third quarter worth approximately $34,000. Signaturefd LLC grew its holdings in Twist Bioscience by 63.0% in the 3rd quarter. Signaturefd LLC now owns 792 shares of the company’s stock valued at $36,000 after buying an additional 306 shares in the last quarter. EdgeRock Capital LLC bought a new position in Twist Bioscience during the 2nd quarter worth $43,000. Blue Trust Inc. lifted its holdings in shares of Twist Bioscience by 2,912.8% during the second quarter. Blue Trust Inc. now owns 1,175 shares of the company’s stock worth $58,000 after buying an additional 1,136 shares in the last quarter. Finally, DekaBank Deutsche Girozentrale bought a new stake in shares of Twist Bioscience in the second quarter valued at about $61,000.

Analysts Set New Price Targets

Several equities research analysts have recently commented on the company. Barclays cut their price objective on Twist Bioscience from $55.00 to $52.00 and set an “overweight” rating for the company in a report on Tuesday, November 19th. TD Cowen reiterated a “buy” rating and issued a $58.00 price target on shares of Twist Bioscience in a research note on Tuesday, November 26th. Leerink Partners boosted their price objective on shares of Twist Bioscience from $45.00 to $48.00 and gave the stock a “market perform” rating in a research note on Thursday, October 17th. Evercore ISI upped their target price on shares of Twist Bioscience from $52.00 to $56.00 and gave the company an “outperform” rating in a report on Tuesday, October 1st. Finally, Scotiabank lifted their price target on Twist Bioscience from $50.00 to $54.00 and gave the stock a “sector outperform” rating in a report on Tuesday, November 19th. One research analyst has rated the stock with a sell rating, one has issued a hold rating and seven have assigned a buy rating to the company’s stock. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus price target of $51.00.

About Twist Bioscience

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.